only with
Laurus Labs Ltd.
Laurus Labs
Laurus Labs Ltd. live price is ₹ 0.00. Price change 0.00, 0.00 percent.
₹ 0.00
0.00 (0.00)%
Healthcare
Large-cap - With a market cap of ₹1097.97 Cr.
| EX-Date | Purpose |
|---|---|
| 29 04 2021 | Third Interim Dividend & Audited Results |
| 29 07 2021 | Quarterly Results |
| 28 10 2021 | Quarterly Results & Interim Dividend |
| 27 01 2022 | Quarterly Results |
| 28 04 2022 | Interim Dividend & Audited Results |
| 27 07 2022 | Quarterly Results |
| 21 10 2022 | Quarterly Results & Interim Dividend |
| 30 01 2023 | Quarterly Results |
| 27 04 2023 | Second Interim Dividend & Audited Results |
| 27 07 2023 | Quarterly Results |
| 20 10 2023 | Quarterly Results & Interim Dividend |
| 24 01 2024 | Quarterly Results |
| 24 10 2024 | Quarterly Results & Interim Dividend |
| 24 04 2025 | Interim Dividend & Audited Results |
| 25 07 2025 | Quarterly Results |
| 23 10 2025 | Quarterly Results & Interim Dividend |
| 23 01 2026 | Quarterly Results |
| 30 04 2026 | Audited Results & Interim Dividend |
| 24 07 2026 | Quarterly Results |
News
Laurus Labs invests Rs 12.09 crore in KRPL
Consequent to this investment, the total holding of the company in KRPL is 2,11,68,000 equity shares of Rs 10 each
Laurus Labs submits analyst meet intimation
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 2899.60 Mln, in the June 2026 quarter
Laurus Labs informs about AGM
Laurus Labs informs about newspaper advertisements
Laurus Labs informs about press release
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 1917.90 Mln, in the March 2026 quarter
Laurus Labs informs about disclosure
Laurus Labs - Quaterly Results
Laurus Labs informs about outcome of board meeting
Laurus Labs reports Profit after tax of Rs 1750.80 Mln, in the December 2025 quarter
Laurus Labs informs about certificate
Laurus Labs reports around 10-fold jump in Q2 consolidated net profit
The consolidated total income of the company increased by 36.81% at Rs 1680.43 crore for Q2FY26
Laurus Labs - Quaterly Results
Laurus Labs informs about presentation
Laurus Labs informs about press release
Laurus Labs reports Profit after tax of Rs 2156.70 Mln, in the September 2025 quarter
Laurus Labs informs about investor presentation
Laurus Labs zooms on receiving 531.77 acres of land from Government of Andhra Pradesh
The company has projected Rs 5,630 crore of investment and to provide employment to 6,350 people in three phases over a period of eight years
Laurus Labs receives 531.77 acres of land from Government of Andhra Pradesh
The company has projected Rs 5,630 crore of investment and to provide employment to 6,350 people in three phases over a period of eight years
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 1579.40 Mln, in the June 2025 quarter
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs invests Rs 39.99 crore in Laurus Bio
The company has acquired Series A2 Compulsorily Convertible Preference Shares of Laurus Bio at face value of Rs 100 and premium of Rs 25,850.02
Laurus Labs informs about investor conference
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 2519.00 Mln, in the March 2025 quarter
Laurus Labs - Quaterly Results
Laurus Labs jumps on getting EIR for API manufacturing facility in Andhra Pradesh
The USFDA inspection was conducted from January 27, 2025 to January 31, 2025
Laurus Labs gets EIR for API manufacturing facility in Andhra Pradesh
The USFDA inspection was conducted from January 27, 2025 to January 31, 2025
Laurus Labs gets nod to acquire up to 26% stake in Kurnool Renewables
The investment by the company is expected to be completed within a period of 1 year in three stages
Laurus Labs rises on acquiring equity shares in KRKA
The company has invested Rs 83.30 crore
Laurus Labs acquires equity shares in KRKA
The company has invested Rs 83.30 crore
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 572.70 Mln, in the December 2024 quarter
Laurus Labs - Quaterly Results
Laurus Labs declines as its arm gets one observation from USFDA
Laurus Generics Inc. has undergone a Post-marketing Adverse Drug Experience inspection by USFDA
Laurus Labs’ arm gets one observation from USFDA
Laurus Generics Inc. has undergone a Post-marketing Adverse Drug Experience inspection by USFDA
Laurus Labs’ arm secures equity investments from Eight Roads Ventures, F-Prime Capital, Laurus Labs
The Promoters of Laurus Bio have also been issued share warrants
Laurus Labs submits analyst meet intimation
Laurus Labs informs about standalone and consolidated financial results
Laurus Labs reports Profit after tax of Rs 424.40 Mln, in the September 2024 quarter
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs inaugurates new R&D facility
The 2,00,000 square foot facility is equipped with modern laboratories and infrastructure
Laurus Labs completes USFDA Audit for API Manufacturing Facility at Hyderabad
The audit concluded with zero Form 483 observations
Laurus Labs informs about closure of trading window
Laurus Labs soars on investing over Rs 99 crore in subsidiary
The Company has infused further equity via rights issue keeping in view of the funds requirements of LSPL
Laurus Labs invests over Rs 99 crore in subsidiary
The Company has infused further equity via rights issue keeping in view of the funds requirements of LSPL
Laurus Labs informs about updates on acquisition
Laurus Labs submits analyst meet intimation
Laurus Labs inches up on entering into joint venture agreement with Krka
In this JV Company, Krka will hold 51% and Laurus 49% shareholding
Laurus Labs enters into joint venture agreement with Krka
In this JV Company, Krka will hold 51% and Laurus 49% shareholding
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 426.40 Mln, in the December 2023 quarter
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs informs about board meeting
Laurus Labs falls after USFDA inspects Andhra Pradesh facility of its arm
The inspection was conducted from December 4, 2023 to December 12, 2023
USFDA inspects Andhra Pradesh facility of Laurus Labs’ arm
The inspection was conducted from December 4, 2023 to December 12, 2023
Laurus Labs informs about investor presentation
Laurus Labs informs about analyst meeting
Laurus Labs spurts on acquiring additional stake in Laurus Bio
With this acquisition the Company holds 87.59% shareholding (on fully diluted basis) in Laurus Bio
Laurus Labs acquires additional stake in Laurus Bio
With this acquisition the Company holds 87.59% shareholding (on fully diluted basis) in Laurus Bio
Laurus Labs informs about update on acquisition of shares
Laurus Labs informs about un-audited financial results
Laurus Labs reports 83% fall in Q2 consolidated net profit
Total consolidated income of the company decreased by 22.24% at Rs 1226.23 crore for Q2FY24
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 466.70 Mln, in the September 2023 quarter
Laurus Labs informs about investor meeting
Laurus Labs to acquire stake in Laurus Bio
With this acquisition, the shareholding of the Company in Laurus Bio will become 87.58% on fully diluted basis
Laurus Labs informs about analyst meet
Laurus Labs reports 89% fall in Q1 consolidated net profit
Total consolidated income of the company decreased by 23.06% at Rs 1,185.39 crore for Q1FY24
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 130.70 Mln, in the June 2023 quarter
Laurus Labs - Quaterly Results
Laurus Labs informs about earnings conference call
Laurus Labs informs about earnings conference call
Laurus Labs informs about scrutinizer’s report
Laurus Labs informs about AGM
Laurus Labs informs about AGM and annual report
Laurus Labs informs about analyst meet
Laurus labs surges on inking pact with IIT Kanpur
As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development
Laurus labs inks pact with IIT Kanpur
As per MOA, Laurus labs will in-license few gene therapy assets and will provide research grant for advancing these products through the pre-clinical development
Laurus Labs moves up on getting EIR from USFDA for Andhra Pradesh manufacturing facility
Earlier, USFDA had conducted inspection at the said manufacturing unit from February 06, 2023 to February 10, 2023
Laurus Labs gets EIR from USFDA for Andhra Pradesh manufacturing facility
Earlier, USFDA had conducted inspection at the said manufacturing unit from February 06, 2023 to February 10, 2023
Laurus Labs informs about disclosure
Laurus Labs informs about secretarial compliance report
Laurus Labs informs about updates
Laurus Labs gains on getting USFDA’s tentative approval for Oral Dispersible Film Dolutegravir
This innovative paediatric drug administration through Oral Dispersible Film technology developed by Laurus Labs will simplify the drug administration in children
Laurus Labs gets USFDA’s tentative approval for Oral Dispersible Film Dolutegravir
his innovative paediatric drug administration through Oral Dispersible Film technology developed by Laurus Labs will simplify the drug administration in children
Laurus Labs reports 54% fall in Q4 consolidated net profit
Total consolidated income of the company decreased by 3.05% at Rs 1,382.61 crore for Q4FY23
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs reports Profit after tax of Rs 1022.80 Mln, in the March 2023 quarter
Laurus Labs informs about closure of trading window
Laurus Labs informs about analyst meeting
Laurus Labs informs about disclosure
Laurus Labs informs about transcript of earnings call
Laurus Labs reports 31% rise in Q3 consolidated net profit
Total consolidated income of the company increased by 49.53% to Rs 1,546.25 crore for the quarter under review
Laurus Labs reports Profit after tax of Rs 1990.50 Mln, in the December 2022 quarter
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs - Quaterly Results
Laurus Labs informs about closure of trading window
Laurus Labs informs about flash fire in manufacturing plant
Laurus Labs rises on entering into share subscription agreement with Ethan Energy India
This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant
Laurus Labs enters into share subscription agreement with Ethan Energy India
This will enable the Company to consume 100% of the solar energy to be supplied by Ethan Energy India from their 10 MW Solar Energy plant
USFDA completes pre-approval inspection at Laurus Labs’ facility in Andhra Pradesh
The company has been issued a Form 483 with one observation